Abnormal cytoplasmic dyslocalisation and/or reduction of nucleophosmin protein level rarely occurs in myelodysplastic syndromes

References

• Korgaonkar C, Hagen J, Tompkins V, Frazier A A, Allamargot C, Quelle F W, et al. Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function. Mol Cell Biol 2005; 25: 1258–1271
   PubMed Web of Science ®Google Scholar
• Kurki S, Peltonen K, Latonen L, Kiviharju T M, Ojala P M, Meek D, et al. Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation. Cancer Cell 2004; 5: 465–475
   PubMed Web of Science ®Google Scholar
• Colombo E, Marine J C, Danovi D, Falini B, Pelicci P G. Nucleophosmin regulates the stability and transcriptional activity of p53. Nat Cell Biol 2002; 4: 529–533
   PubMed Web of Science ®Google Scholar
• Borer R A, Lehner C F, Eppenberger H M, Nigg E A. Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell 1989; 56: 379–390
   PubMed Web of Science ®Google Scholar
• Chan W Y, Liu Q R, Borjigin J, Busch H, Rennert O M, Tease L A, et al. Characterization of the cDNA encoding human nucleophosmin and studies of its role in normal and abnormal growth. Biochemistry 1989; 28: 1033–1039
   PubMed Web of Science ®Google Scholar
• Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005; 352: 254–266
   PubMed Web of Science ®Google Scholar
• Grisendi S, Mecucci C, Falini B, Pandolfi P P. Nucleophosmin and cancer. Nat Rev Cancer 2006; 6: 493–505
   PubMed Web of Science ®Google Scholar
• Naoe T, Suzuki T, Kiyoi H, Urano T. Nucleophosmin: a versatile molecule associated with hematological malignancies. Cancer Sci 2006; 97: 963–969
   PubMed Web of Science ®Google Scholar
• Morris S W, Kirstein M N, Valentine M B, Dittmer K, Shapiro D N, Look A T, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1995; 267: 316–317
   PubMed Web of Science ®Google Scholar
• Yoneda-Kato N, Look A T, Kirstein M N, Valentine M B, Raimondi S C, Cohen K J, et al. The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1. Oncogene 1996; 12: 265–275
   PubMed Web of Science ®Google Scholar
• Redner R L, Rush E A, Faas S, Rudert W A, Corey S J. The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood 1996; 87: 882–886
   PubMed Web of Science ®Google Scholar
• Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 2006; 107: 4011–4020
   PubMed Web of Science ®Google Scholar
• Verhaak R G, Goudswaard C S, van Putten W, Bijl M A, Sanders M A, Hugens W, et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 2005; 106: 3747–3754
   PubMed Web of Science ®Google Scholar
• Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli M F, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005; 106: 3733–3739
   PubMed Web of Science ®Google Scholar
• Dohner K, Schlenk R F, Habdank M, Scholl C, Rucker F G, Corbacioglu A, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 2005; 106: 3740–3746
   PubMed Web of Science ®Google Scholar
• Suzuki T, Kiyoi H, Ozeki K, Tomita A, Yamaji S, Suzuki R, et al. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood 2005; 106: 2854–2861
   PubMed Web of Science ®Google Scholar
• Grisendi S, Bernardi R, Rossi M, Cheng K, Khandker L, Manova K, et al. Role of nucleophosmin in embryonic development and tumorigenesis. Nature 2005; 437: 147–153
   PubMed Web of Science ®Google Scholar
• Berger R, Busson M, Baranger L, Helias C, Lessard M, Dastugue N, et al. Loss of the NPM1 gene in myeloid disorders with chromosome 5 rearrangements. Leukemia 2006; 20: 319–321
   PubMed Web of Science ®Google Scholar
• Oki Y, Jelinek J, Beran M, Verstovsek S, Kantarjian H M, Issa J P. Mutations and promoter methylation status of NPM1 in myeloproliferative disorders. Haematologica 2006; 91: 1147–1148
   PubMed Web of Science ®Google Scholar
• Ozeki K, Kiyoi H, Hirose Y, Iwai M, Ninomiya M, Kodera Y, et al. Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood 2004; 103: 1901–1908
   PubMed Web of Science ®Google Scholar
• Xu J L, Lai R, Kinoshita T, Nakashima N, Nagasaka T. Proliferation, apoptosis, and intratumoral vascularity in multiple myeloma: correlation with the clinical stage and cytological grade. J Clin Pathol 2002; 55: 530–534
   PubMed Web of Science ®Google Scholar
• Corey S J, Minden M D, Barber D L, Kantarjian H, Wang J C, Schimmer A D. Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer 2007; 7: 118–129
   PubMed Web of Science ®Google Scholar
• Sportoletti P, Grisendi S, Majid S M, Cheng K, Clohessy J G, Viale A, et al. Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse. Blood 2008; 111: 3859–3862
   PubMed Web of Science ®Google Scholar